WallStreetZenWallStreetZen

NASDAQ: ALRN
Aileron Therapeutics Inc Stock Ownership - Who owns Aileron Therapeutics?

Insider buying vs selling

Have Aileron Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
James Brian WindsorPresident and COO2023-12-15225$3.37
$758.25Buy
James Brian WindsorPresident and COO2023-11-205,076$1.97
$9.99kBuy

1 of 1

ALRN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALRN insiders and whales buy or sell their stock.

ALRN Shareholders

What type of owners hold Aileron Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Muneer A. Satter97.86%16,609,449$70.59MInsider
Reinhard J. Ambros15.02%2,549,982$10.84MInsider
Novartis Bioventures Ltd12.25%2,079,394$8.84MInsider
Brian M. Gallagher Jr.8.43%1,431,519$6.08MInsider
Lv Management Group LLC6.45%1,094,987$4.65MInsider
Armen Shanafelt6.45%1,094,987$4.65MInsider
Excel Medical Fund LP5.99%1,016,100$4.32MInsider
Alerce Investment Management LP4.89%830,466$3.53MInstitution
Cvf LLC4.22%716,180$3.04MInsider
Roche Holding Ltd4.16%706,233$3.00MInsider

1 of 3

ALRN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALRN3.39%96.61%Net Buying
ALVR14.62%85.38%Net BuyingNet Selling
RVPH18.78%38.25%
ELTX3.25%92.54%Net Buying
SLS6.21%13.47%Net Selling

Aileron Therapeutics Stock Ownership FAQ

Who owns Aileron Therapeutics?

Aileron Therapeutics (NASDAQ: ALRN) is owned by 6.27% institutional shareholders, 178.48% Aileron Therapeutics insiders, and 0.00% retail investors. Muneer A. Satter is the largest individual Aileron Therapeutics shareholder, owning 16.61M shares representing 97.86% of the company. Muneer A. Satter's Aileron Therapeutics shares are currently valued at $83.05M.

If you're new to stock investing, here's how to buy Aileron Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.